Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NASDAQ:GMAB NASDAQ:NAMS NASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$236.60-1.6%$232.17$153.49▼$250.74$14.79B0.41694,651 shs145,066 shsGMABGenmab A/S$26.44-0.4%$27.04$19.80▼$35.43$16.51B0.861.77 million shs1.73 million shsNAMSNewAmsterdam Pharma$34.48-2.7%$32.33$16.78▼$42.21$4.02B0.02949,536 shs737,094 shsSMMTSummit Therapeutics$16.06-4.8%$18.81$13.83▼$30.98$12.47B-1.253.21 million shs1.13 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%+0.77%-1.63%+11.18%+52.60%GMABGenmab A/S0.00%+0.57%-7.04%-11.62%+33.50%NAMSNewAmsterdam Pharma0.00%-8.49%+2.19%+2.34%+87.71%SMMTSummit Therapeutics0.00%-6.69%-32.92%+12.77%-29.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$236.60-1.6%$232.17$153.49▼$250.74$14.79B0.41694,651 shs145,066 shsGMABGenmab A/S$26.44-0.4%$27.04$19.80▼$35.43$16.51B0.861.77 million shs1.73 million shsNAMSNewAmsterdam Pharma$34.48-2.7%$32.33$16.78▼$42.21$4.02B0.02949,536 shs737,094 shsSMMTSummit Therapeutics$16.06-4.8%$18.81$13.83▼$30.98$12.47B-1.253.21 million shs1.13 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S0.00%+0.77%-1.63%+11.18%+52.60%GMABGenmab A/S0.00%+0.57%-7.04%-11.62%+33.50%NAMSNewAmsterdam Pharma0.00%-8.49%+2.19%+2.34%+87.71%SMMTSummit Therapeutics0.00%-6.69%-32.92%+12.77%-29.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.95Moderate Buy$291.7823.32% UpsideGMABGenmab A/S 2.83Moderate Buy$39.0747.75% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.0039.19% UpsideSMMTSummit Therapeutics 2.50Moderate Buy$27.5871.75% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, GMAB, ASND, and SMMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ASNDAscendis Pharma A/S EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$329.005/11/2026ASNDAscendis Pharma A/S BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$342.00 ➝ $345.005/8/2026GMABGenmab A/S Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/8/2026ASNDAscendis Pharma A/S Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$330.00 ➝ $326.005/4/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $23.005/1/2026SMMTSummit Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$17.00 ➝ $16.004/30/2026GMABGenmab A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $38.004/27/2026GMABGenmab A/S Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026GMABGenmab A/S BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/22/2026GMABGenmab A/S The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy4/21/2026NAMSNewAmsterdam Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$814.57M18.12N/AN/A($2.97) per share-79.66GMABGenmab A/S$3.90B4.23$1.60 per share16.49$9.10 per share2.91NAMSNewAmsterdam Pharma$22.50M179.16N/AN/A$5.97 per share5.78SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$258M$8.6727.3523.06N/A57.87%N/A-8.37%8/6/2026 (Estimated)GMABGenmab A/S$963M$1.3220.0615.931.5421.05%15.34%8.94%8/6/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)SMMTSummit Therapeutics-$1.08B-$1.60N/AN/AN/AN/A-291.24%-243.07%N/ALatest NAMS, GMAB, ASND, and SMMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ASNDAscendis Pharma A/S$0.21$0.32+$0.11$11.29$362.47 million$285.45 million5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million4/30/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/A3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million2/23/2026Q4 2025SMMTSummit Therapeutics-$0.22-$0.29-$0.07-$0.29$75.47 millionN/A2/18/2026Q4 2025GMABGenmab A/S$0.46$0.05-$0.41$0.0470$1.06 billion$1.06 billion2/18/2026Q4 2025NAMSNewAmsterdam Pharma-$0.40-$0.63-$0.23-$0.63$0.92 million$0.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/S0.791.000.72GMABGenmab A/S0.872.182.17NAMSNewAmsterdam PharmaN/A9.769.76SMMTSummit TherapeuticsN/A7.417.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AGMABGenmab A/S7.07%NAMSNewAmsterdam Pharma89.89%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%GMABGenmab A/S1.54%NAMSNewAmsterdam Pharma12.74%SMMTSummit Therapeutics83.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,18962.38 million37.43 millionOptionableGMABGenmab A/S3,029623.51 million613.91 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableNAMS, GMAB, ASND, and SMMT HeadlinesRecent News About These CompaniesSummit Therapeutics (NASDAQ:SMMT) Lowered to "Sell" Rating by Wall Street ZenMay 18 at 1:09 AM | americanbankingnews.comSummit Therapeutics PLC $SMMT Stock Holdings Decreased by Vanguard Group Inc.May 11, 2026 | marketbeat.comWall Street Zen Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Hold"May 10, 2026 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at Wall Street ZenMay 10, 2026 | marketbeat.comQ2 EPS Estimate for Summit Therapeutics Boosted by AnalystMay 8, 2026 | marketbeat.comQ2 Earnings Forecast for SMMT Issued By HC WainwrightMay 7, 2026 | marketbeat.comSMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackMay 4, 2026 | zacks.comSummit Therapeutics: More Uncertainty Heading Into The ASCO PlenaryMay 4, 2026 | seekingalpha.comBuy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash RunwaysMay 4, 2026 | 247wallst.comSummit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 4, 2026 | globenewswire.comHC Wainwright Issues Pessimistic Forecast for Summit Therapeutics (NASDAQ:SMMT) Stock PriceMay 4, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adagene (ADAG) and Summit Therapeutics (SMMT)May 3, 2026 | theglobeandmail.comSummit Therapeutics (SMMT) Receives a Rating Update from a Top AnalystMay 3, 2026 | theglobeandmail.comSMMT stock plunges on wider Q1 loss, lung cancer clinical trial updateMay 2, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Issues Earnings ResultsMay 2, 2026 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Sell" at Wall Street ZenMay 2, 2026 | marketbeat.comSummit Therapeutics Shock Move Hits Nasdaq FuturesMay 1, 2026 | kalkinemedia.comKSummit Therapeutics falls after update on Akeso-partnered lung cancer trialMay 1, 2026 | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Time to Sell?May 1, 2026 | marketbeat.comSummit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026April 30, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, GMAB, ASND, and SMMT Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$236.60 -3.90 (-1.62%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Genmab A/S NASDAQ:GMAB$26.44 -0.10 (-0.36%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.NewAmsterdam Pharma NASDAQ:NAMS$34.48 -0.96 (-2.70%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Summit Therapeutics NASDAQ:SMMT$16.06 -0.81 (-4.80%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Datavault Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
